Table 2.
Subsequent therapies
| IPI-treated cohort | Non-IPI–treated cohort | |||
|---|---|---|---|---|
| IPI-noOther (n = 780)a | IPI-Other (n = 314) | Other-Other (n = 205) | Other-IPI (n = 57) | |
| Systemic therapy, no. (%) | 0 | 313 (100) | 54 (26) | 57 (100) |
| Immunotherapy | 0 | 181 (58) | 18 (9) | 57 (100) |
| Anti–PD-1 agentb | 0 | 161 (51) | 18 (9) | 10 (18) |
| Anti–CTLA-4 agentc | 0 | 34 (11) | 0 | 57 (100) |
| Other systemic therapy, no. (%) | 0 | 186 (59) | 43 (21) | 15 (26) |
| BRAF ± MEK inhibitord | 0 | 103 (33) | 18 (9) | 8 (14) |
| Chemotherapye | 0 | 110 (35) | 33 (16) | 12 (21) |
| Other investigational agentf | 0 | 11 (4) | 1 (<1) | 0 |
| Otherg | 0 | 11 (4) | 0 | 0 |
| Radiotherapyh | 138 (18) | 101 (32) | 21 (10) | 16 (28) |
CTLA-4 cytotoxic T-lymphocyte antigen 4, IPI ipilimumab, PD-1 programmed death 1.
aRadiotherapy was allowed with ipilimumab in this cohort; therefore, it was not considered subsequent therapy
bPembrolizumab or nivolumab
cIpilimumab
dDabrafenib ± trametinib or vemurafenib ± cobimetinib
eBleomycin, carboplatin, cisplatin, combinations of antineoplastic agents, cyclophosphamide, dacarbazine, dactinomycin, docetaxel, etoposide, fotemustine, gemcitabine, lomustine, melphalan, paclitaxel, paclitaxel + carboplatin, temozolomide, treosulfan, trofosfamide, vinblastine, vincristine, vindesine, or vinorelbine
fBevacizumab or imatinib
gAldesleukin, antineoplastic and immunomodulating agents, interferon-alpha, interleukin-2, melanoma vaccine, other therapeutic products, or monoclonal antibodies
hRadiation, radiosurgery, radiotherapy, or yttrium (90Y)